<DOC>
	<DOCNO>NCT00617253</DOCNO>
	<brief_summary>This phase 1/2a trial conduct Europe . The first part trial dose escalation safety trial determine maximum tolerate dose rIL-21 administer combination sunitinib . The second part , schedule start September 2008 , randomise 2-arm trial compare anti-tumour effect rIL-21 plus sunitinib sunitinib alone .</brief_summary>
	<brief_title>Combination Recombinant Human IL-21 ( rIL-21 ) Sunitinib Stage IV Renal Cell Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically verify surgically incurable stage IV Renal Cell Carcinoma ECOG performance status 0 1 ( i.e . good performance status ) Life expectancy least 3 month Prior systemic therapy metastatic disease Radiotherapy within last 4 week prior start treatment Receipt investigational drug within 3 month start treatment History active malignancy within five year prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>